MedTrace Logo

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

NCT03397706 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-03-20

Study results available
· View outcomes & findings →

Summary

A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+ lymphomas).

Conditions

  • Epstein-Barr Virus-Associated Lymphoma
  • Lymphoproliferative Disorders

Interventions

COMBINATION_PRODUCT

VRx-3996 and valganciclovir

second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)

Sponsors & Collaborators

  • Viracta Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jill DeFratis Robinson · Viracta Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-29
Primary Completion
2023-04-01
Completion
2023-05-04
FDA Drug
Yes

Countries

  • United States
  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03397706 on ClinicalTrials.gov